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Abstract
 
We evaluated the effects of ectopic granulocyte/macrophage colony-stimulating factor
(GM-CSF) signals on hematopoietic commitment and differentiation. Lineage-restricted pro-
genitors purified from mice with the ubiquitous transgenic human GM-CSF receptor
(hGM-CSFR) were used for the analysis. In cultures with hGM-CSF alone, hGM-CSFR–
expressing (hGM-CSFR
 
 
 
) granulocyte/monocyte progenitors (GMPs) and megakaryocyte/
erythrocyte progenitors (MEPs) exclusively gave rise to granulocyte/monocyte (GM) and
megakaryocyte/erythroid (MegE) colonies, respectively, providing formal proof that GM-CSF
signals support the GM and MegE lineage differentiation without affecting the physiological
myeloid fate. hGM-CSFR transgenic mice were crossed with mice deficient in interleukin
(IL)-7, an essential cytokine for T and B cell development. Administration of hGM-CSF in
these mice could not restore T or B lymphopoiesis, indicating that enforced GM-CSF signals
cannot substitute for IL-7 to promote lymphopoiesis. Strikingly, 
 
 
 
50% hGM-CSFR
 
  
 
common
lymphoid progenitors (CLPs) and 
 
 
 
20% hGM-CSFR
 
  
 
pro-T cells gave rise to granulocyte,
monocyte, and/or myeloid dendritic cells, but not MegE lineage cells in the presence of
hGM-CSF. Injection of hGM-CSF into mice transplanted with hGM-CSFR
 
  
 
CLPs blocked
their lymphoid differentiation, but induced development of GM cells in vivo. Thus, hGM-CSF
transduces permissive signals for myeloerythroid differentiation, whereas it transmits potent in-
structive signals for the GM differentiation to CLPs and early T cell progenitors. These data
suggest that a majority of CLPs and a fraction of pro-T cells possess plasticity for myelomono-
cytic differentiation that can be activated by ectopic GM-CSF signals, supporting the hypothesis
that the down-regulation of GM-CSFR is a critical event in producing cells with a lymphoid-
restricted lineage potential.
Key words: commitment • lineage conversion • cytokine • plasticity
 
Introduction
 
Hematopoietic stem cells (HSCs)
 
* 
 
give rise to committed
progenitors and undergo terminal differentiation into ma-
ture blood cells. Cytokines are one of the most important
exogenous factors capable of regulating hematopoietic de-
velopment. All developing blood cells express a variety of
cytokine receptors, which transduce signals supportive of
cell differentiation and survival. However, it is still unclear
whether cytokines can play a role in hematopoietic lineage
determination (1, 2). Lineage-specific action of cytokines
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Abbreviations used in this paper:
 
 CLP, common lymphoid progenitor;
CMP, common myeloid progenitor; EpoR, erythropoietin receptor;
GM, granulocyte/monocyte; GMP, granulocyte/monocyte progenitor;
hGM-CSF, human GM-CSF; HSC, hematopoietic stem cell; MegE,
megakaryocyte/erythroid; MEP, megakaryocyte/erythrocyte progenitor;
Slf, steel factor; Tpo, thrombopoietin.T
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could be achieved by several mechanisms. A diverse distri-
bution of cytokine receptors in the hematopoietic system
could directly represent the range of cell types that are re-
sponsive to cognate cytokines. Furthermore, each cell type
could possess different accessibility for lineage-affiliated
genes by epigenetic programs (3). These preconditions,
specific for each cell type, could be important for cell lin-
eage potential in response to cytokine signals.
It has been suggested that cytokine signals do not play a
role in myeloid lineage determination. Mice with targeted
mutations in myeloid cytokines or their receptors do not
display a complete loss of specific lineage cells (4–7), sug-
gesting that myeloid cytokine signals are largely redundant.
Transgenic receptors for myeloid cytokines such as human
GM-CSF (hGM-CSF; 8), human G-CSF (9, 10), and mu-
rine IL-5 (11) have been ubiquitously expressed in murine
hematopoietic cells. In these models, binding of transgenic
receptors by their cognate cytokines alone can induce the
differentiation of megakaryocyte/erythroid (MegE) as well
as granulocyte/monocyte (GM) lineage cells. Constitutive
expression of the activated form of erythropoietin receptors
(EpoRs) in bone marrow cells also supports GM differenti-
ation (12). Finally, mice with a targeted chimeric mutation
in the G-CSFR, where the cytoplasmic domain is replaced
by the EpoR, do not display any abnormality in their he-
matopoietic development (13). Thus, signals from these
myeloerythroid cytokine receptors might be largely redun-
dant, which might play a permissive role in myeloerythroid
commitment. Therefore, the lineage-specific action of
these myeloid cytokines might be dependent on the lin-
eage-specific expression of their receptors.
In contrast, T and B lymphoid development is supported
by nonredundant IL-7 signals. IL-7R is a high affinity re-
ceptor complex composed of the IL-7R
 
  
 
chain and the
common cytokine receptor 
 
  
 
chain (
 
 
 
c). Genetic ablation
of either IL-7, IL-7R
 
 
 
, or 
 
 
 
c causes a significant loss of T
and B cells, resulting in SCID (14–17). IL-7 exerts
“trophic” effects on 
 
   
 
T cell development, but is indis-
pensable for the rearrangement of the TCR
 
  
 
chain (18)
and the V segments of IgH genes (19). We and others have
shown that IL-7R signals maintain T cell survival (20), and
that enforced expression of Bcl-2 restored 
 
   
 
T, but not
 
   
 
T or B cell development in IL-7R
 
 
 
 
 
/
 
  
 
and 
 
 
 
c
 
 
 
/
 
  
 
mice
(20–22). Nonetheless, the earliest lymphoid progenitors
(common lymphoid progenitors [CLPs]) are present in IL-
7
 
 
 
/
 
  
 
mice (23), suggesting that the role of IL-7 signals in
lymphoid commitment could also be permissive.
It is of interest that the cytokine requirement for my-
elopoiesis is largely redundant, whereas for lymphopoiesis, it
is highly dependent on lymphoid-specific IL-7 signals. It is
possible that this apparent difference in cytokine depen-
dence is simply due to differences in the distribution of cy-
tokine receptors in the lymphoid and myeloid pathways. In
fact, the earliest myeloid progenitors (common myeloid
progenitors [CMPs]; 24) express multiple myeloerythroid
cytokine receptors but do not express IL-7R, whereas lym-
phoid progenitors do not express myeloid cytokine recep-
tors (25). Thus, it is possible that enforced GM-CSFR, like
 
IL-7R, transduces signals that are supportive of lymphoid
development because transgenic hGM-CSFR could trans-
duce survival-promoting signals (26). Our recent studies,
however, suggest that myeloid cytokine signals could exert
effects on lymphoid development that are distinct from IL-7
signals. The enforced expression of IL-2 signals can instruct
a fraction of CLPs to differentiate into GM cells at the ex-
pense of lymphoid differentiation (27). The ectopic IL-2
signals at the CLP stage may overlap with the GM-CSF sig-
nals, because a few percent of CLPs with retrovirally trans-
duced hGM-CSFR
 
  
 
can also form GM colonies (27).
These data led us to directly analyze the effect of ectopic
GM-CSF signals on lineage commitment at the lymphoid
and myeloid branchpoints. We have identified myeloid-
and lymphoid-committed progenitor populations in mu-
rine hematopoiesis, including CMPs, granulocyte/mono-
cyte progenitors (GMPs), megakaryocyte/erythrocyte
progenitors (MEPs; 24), and CLPs (23). For this study, we
purified these progenitors from mice ubiquitously express-
ing the hGM-CSFR
 
 
 
/
 
 
 
c transgene (8), and tested the ef-
fect of hGM-CSF on their lineage potentials. Our results
indicate that ectopic GM-CSF signals play a permissive role
in lineage commitment throughout the myeloid, but not
the lymphoid pathway, and induce a significant fraction of
CLPs and pro-T cells to convert into the GM lineage at the
expense of lymphoid differentiation. Thus, GM-CSF sig-
nals can reactivate GM-specific differentiation programs in
early lymphoid progenitors, suggesting that the down-reg-
ulation of myeloid cytokine receptors is a critical event in
lymphoid commitment.
 
Materials and Methods
 
Mice.
 
C57B6 (Ly5.1 or Ly5.2) and C57B6-H-2L
 
d
 
-hGM-
CSFR
 
 
 
/
 
 
 
c double transgenic mice (8) were used in this study.
Expression of hGM-CSFR in all hematopoietic cells has been
shown in previous studies (8). IL-7R
 
 
 
 
 
/
 
  
 
(14) and IL-7
 
 
 
/
 
  
 
mice
(15) were obtained from The Jackson Laboratory and provided
by R. Murray (DNAX Research Institute of Cellular and Molec-
ular Biology, Palo Alto, CA), respectively. Both IL-7R
 
 
 
 
 
/
 
  
 
and
IL-7
 
 
 
/
 
  
 
mice were crossed with C57B6 mice for seven genera-
tions. Mice were bred and maintained in the Research Animal
Facility at the Dana-Farber Cancer Institute in accordance with
their guidelines.
 
Cell Staining and Sorting.
 
Sorting of myeloid progenitors was
accomplished by staining bone marrow cells with rat anti–IL-
7R
 
  
 
chain monoclonal antibodies (A7R34; eBioscience) and pu-
rified or PE-Cy5 (Tricolor)–conjugated rat antibodies specific for
the following lineage markers: CD3 (CT-CD3), CD4 (RM4-5),
CD8 (5H10), B220 (6B2), Gr-1 (8C5), TER119, and CD19
(6D5; Caltag). IL-7R
 
 
 
  
 
Lin
 
  
 
cells were removed with sheep
anti–rat IgG–conjugated magnetic beads (Dynabeads M-450;
Dynal) and the remaining cells were stained with goat PE-Cy5–
conjugated anti–rat IgG (Caltag). Cells were then stained with
PE-conjugated anti-Fc
 
 
 
RII/III (2.4G2), FITC-conjugated anti-
CD34 (RAM34), APC-conjugated anti-c-Kit (2B8), and bio-
tinylated anti–Sca-1 (E13-161-7) monoclonal antibodies (BD
Biosciences), followed by avidin-APC-Cy7 (Caltag). Myeloid
progenitors were sorted as Lin
 
  
 
Sca-1
 
  
 
c-Kit
 
  
 
CD34
 
  
 
Fc
 
 
 
RII/
III
 
lo 
 
(CMPs), Lin
 
  
 
Sca-1
 
  
 
c-Kit
 
  
 
CD34
 
  
 
Fc
 
 
 
RII/III
 
hi 
 
(GMPs), andT
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as Lin
 
  
 
Sca-1
 
  
 
c-Kit
 
  
 
CD34
 
  
 
Fc
 
 
 
RII/III
 
lo 
 
(MEPs) as previously
described (24). Sorting of HSCs and CLPs was performed by
staining bone marrow cells with lineage markers as well as FITC-
conjugated anti–Sca-1, biotinylated anti–IL-7R
 
 
 
, and APC-con-
jugated anti–c-Kit antibodies, followed by avidin-PE (Caltag).
HSCs and CLPs were sorted as IL-7R
 
 
 
  
 
Lin
 
  
 
Sca-1
 
hi 
 
c-Kit
 
hi 
 
and
IL-7R
 
 
 
  
 
Lin
 
  
 
Sca-1
 
lo 
 
c-Kit
 
lo 
 
populations, respectively (23). In
some experiments, HSCs were further divided into CD34
 
  
 
long-
term and CD34
 
  
 
short-term HSC populations (28, 29). Detailed
methodologies for staining and sorting can be found at http://
www.metazoa.com (UPL2030 and UPL2001). Pro-T and pro-B
cells were sorted as CD3
 
  
 
CD4
 
  
 
CD8
 
  
 
NK1.1
 
  
 
c-Kit
 
  
 
CD25
 
 
 
CD44
 
  
 
and CD43
 
  
 
B220
 
  
 
IgM
 
  
 
cells, respectively (30). FITC-
conjugated anti–mouse common 
 
  
 
chain (
 
 
 
c; 9D3) antibodies
(Upstate Biotechnology), and PE-conjugated anti–GM-CSFR
 
 
 
(S-20) antibodies (Santa Cruz Biotechnology, Inc.) were used to
analyze the expression of these cytokine receptors. Cells were
sorted using a highly modified double laser (488/350 nm Enter-
prise II plus 647 nm Spectrum) high speed FACS
 
® 
 
(Moflo-MLS;
DakoCytomation). The five-color sort using both positive and
negative gates in multiple channels usually gives rise to cells that
are 
 
 
 
96% pure, avoiding co-sorting cells stained in a nonspecific
manner. The sample line was washed out by 75% ethanol fol-
lowed by saline between each round of sorting to eliminate re-
maining cells (31). The sorted cells were subjected to another
sorting round using the same gate to eliminate contaminating
cells and doublets (32). This second round of sorting always
yielded target populations with 
 
 
 
99% purity.
 
In Vitro Assays to Determine the Differentiation Potential of Progen-
itors.
 
To test myeloerythroid potential, stem or progenitor cells
were cultured in IMDM-based methylcellulose media (Metho-
cult H4100; StemCell Technologies Inc.), supplemented with
30% FBS, 1% bovine serum albumin, 2 mM 
 
l
 
-glutamine, and 50
 
 
 
M 2-mercaptoethanol. Cytokines such as 20 ng/ml murine steel
factor (Slf), 10 ng/ml murine IL-3, 10 ng/ml murine IL-11, 10
ng/ml murine GM-CSF, 10 ng/ml murine thrombopoietin
(Tpo), 1 U/ml human erythropoietin, and 20 ng/ml hGM-CSF
were added at the start of the culture. All cytokines were pur-
chased from R&D Systems. Colonies were enumerated under an
inverted microscope consecutively from days 5 to 8. The CFU-
Mix such as CFU-GEMMeg, CFU-GEM, and CFU-GEMeg
was determined by Giemsa staining of cells that were picked from
individual colonies using fine drawn-out Pasteur pipettes. To
evaluate myeloid differentiation of CLPs and pro-T cells by
hGM-CSF signals, purified single cells were sorted into Terasaki
plates with IMDM (Invitrogen) containing 20% FBS. To evaluate
B cell differentiation potential, cells were sorted onto irradiated
(3,000 rad) S17 stromal layers in 96-well plates with IMDM with
20% FBS. All cultures were incubated at 37
 
 
 
C in a humidified
chamber under 5% CO
 
2
 
.
 
In Vivo Reconstitution Assays.
 
6,000 purified CLPs from
hGM-CSFR transgenic mice (C57B6-Ly5.2) were intravenously
transplanted into congenic mice (C57B6-Ly5.1) after a sublethal
irradiation dose (450 rad). Mice were killed on days 14 and 28 to
evaluate their progeny by using Ly5.2 as a donor marker. In-
trathymic injection was performed as previously described (33).
3,000 hGM-CSFR
 
  
 
CLPs were directly injected into the thy-
mus, and the phenotype of their progeny was evaluated on days 7
and 14. hGM-CSF (500 ng 
 
  
 
2/day) or PBS was subcutaneously
administered for 5 d.
 
Analysis of Gene Expression from Total RNA.
 
Total RNA was
extracted from 2,000 double-sorted cells for each population and
reverse transcribed to cDNA as previously described (24). An ali-
 
quot of cDNA was analyzed for specific genes (primers provided
upon request). The HPRT gene was also amplified and used as a
control. PCR amplification consisted of an initial denaturation
step at 94
 
 
 
C for 2 min, followed by 28–32 cycles at 94
 
 
 
C for 30 s,
annealing for 30 s, and extension at 72
 
 
 
C for 90 s in each cycle.
PCR products were subjected to electrophoresis on an ethidium
bromide–stained 1.8% agarose gel. PCR amplification for each
experiment was repeated for two or more independently pre-
pared cDNA samples. Relative gene expression quantitation was
accomplished by comparing the level of any transcript in the tar-
get samples to that in control cDNA prepared from 2 
 
  
 
10
 
5
 
whole bone marrow cells, as previously reported (24). The PCR
cycles for each target gene were at a point when the reaction is in
the exponential phase, to obtain a linear correlation between
pixel density units of the PCR products and the amount of con-
trol cDNA applied (24). After PCR amplification, each product
was visualized by the Gel Doc 1000 Video Gel Documentation
System, and pixel density units of each product was read by Mo-
lecular Analyst Software (Bio-Rad Laboratories).
 
Evaluation of TCR
 
  
 
Rearrangement.
 
PCR analysis was used
for detecting the rearrangement of the TCR
 
  
 
genes as previously
described (34). In brief, 2,000 sorted cells were incubated at 94
 
 
 
C
for 10 min in 0.5% Tween D in PCR buffer before the PCR re-
action. The primer sequences used for the TCR
 
  
 
gene in the
first PCR reaction were 5
 
 
 
-TAGGCACCTGTGGGGAA-
GAAAC-3
 
  
 
(D
 
 
 
2.1 ext) and 5
 
 
 
-TGAGAGCTGTCTCCTAC-
TATC-3
 
  
 
(J 2.7 ext). 1/5 aliquots were further amplified with
an internal primer pair, 5 -GTATCACGATGTAACATTGTG-3 
(D 2.1 int) and 5 -GGAAGCGAGAGATGTGAATC-3  (J 2.7
int). The samples were denatured (at 94 C for 30 s), annealed (at
58 C for 2 min), and extended (at 72 C for 3 min) for 35 cycles.
Amplified DNA was subjected to electrophoresis in a 1.2% aga-
rose gel.
Results
Distribution of Cytokine Receptors in Hematopoiesis. Fig. 1
A depicts the hematopoietic developmental tree and the
progenitors used in this study. We analyzed the distribution
of mGM-CSFR , IL-3R , EpoR, and IL-7R  by RT-
PCR in murine stem and progenitor populations (23, 24).
In this analysis, we separated Lin  Sca-1  c-Kit  HSC pop-
ulation (35) into CD34  Sca-1  c-Kit  HSCs that possess
long-term reconstituting activity at the single cell level (28),
and their descendants, CD34  Sca-1  c-Kit  short-term
HSCs (28, 29). As shown in Fig. 1 B, the expression of
mGM-CSFR  and IL-3R  is initiated at the short-term
HSC stage, and gradually up-regulated along the my-
elomonocytic pathway including CMPs and GMPs,
whereas they are down-regulated in CLPs and MEPs.
FACS® analysis showed that murine  c is expressed in all
hematopoietic cells (not depicted). Thus, the expression of
 c-related cytokine receptors such as GM-CSFR and IL-
3R are progressively up-regulated along the myelomono-
cytic differentiation pathway, but down-regulated if cells
commit to the lymphoid or the MegE lineages. EpoR is
up-regulated during the development from long-term
HSCs to MEPs, but down-regulated in GMPs or CLPs. In
contrast, lymphoid-related IL-7R  is exclusively expressed
in CLPs, but not in HSCs or myeloid progenitors. InT
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H-2Ld-hGM-CSFR / c double transgenic mice (8), hGM-
CSFR / c transgenes are driven by the MHC class I pro-
moter, and most hematopoietic cells express hGM-CSFR.
As shown in Fig. 1 C, 85–96% of cells in each progenitor
population were stained with monoclonal anti–hGM-CS-
FR  antibodies. Because hGM-CSFR does not react with
endogenous mGM-CSF, cells in H-2Ld-hGM-CSFR / c
double transgenic mice never receive hGM-CSF signals in
vivo in the absence of hGM-CSF (8). Thus, FACS® analysis
showed that the frequency of each myeloid and lymphoid
progenitor population in hGM-CSFR transgenic mice was
identical to that of wild-type mice (unpublished data).
hGM-CSF Signals Allow Differentiation throughout Myelo-
erythroid Development. Previous studies have shown that
enforced hGM-CSF signals can stimulate murine bone
marrow cells to form a similar proportion of myeloery-
throid colonies supported by a panel of cytokines, suggesting
that hGM-CSF can stimulate maturation of cells without
affecting lineage determination (8, 36). To test this hypo-
thesis, we evaluated the effect of hGM-CSF on lineage read-
outs in HSCs (Lin  Sca-1  c-Kit ) and myeloid progeni-
tors purified from hGM-CSFR transgenic mice (Fig. 2).
Consistent with previous reports, hGM-CSFR  HSCs and
hGM-CSFR  CMPs gave rise to a variety of myeloery-
throid colonies in the presence of hGM-CSF alone. The
efficiency and diversity of colony formation by hGM-CSF
alone were almost identical to those produced by a cyto-
kine cocktail containing Slf, IL-3, IL-11, mGM-CSF, Epo,
and Tpo. Because HSCs cannot form colonies in the ab-
sence of Slf (37), enforced hGM-CSF signals could substi-
tute for Slf signals in addition to myeloerythroid cytokine
signals. Importantly, purified hGM-CSFR   GMPs and
hGM-CSFR  MEPs exclusively generated GM and MegE
colonies, respectively. These data formally prove that
hGM-CSFR transduces permissive signals to myeloery-
throid progenitors and does not affect their physiologically
determined cell fate potential.
hGM-CSF Signals Do Not Substitute for Lymphoid-specific
IL-7. To test whether IL-7 signals in lymphoid develop-
ment can be replaced by hGM-CSF, we crossed hGM-
CSFR transgenic mice with IL-7 /  and IL-7R  /  mice.
Both IL-7 /  hGM-CSFR and IL-7R  /  hGM-CSFR
transgenic mice showed a significant loss of T and B cells,
similar to IL-7 /  and IL-7R  /  mice (14, 15). First, we
injected recombinant hGM-CSF into IL-7 /  hGM-CSFR
transgenic mice. As shown in Fig. 3, the impaired differen-
tiation of T and B cell progenitors was not restored by
hGM-CSF injection. IL-7 /  hGM-CSFR transgenic mice
displayed a  50-fold reduction of thymocyte numbers as
well as a decrease in the frequency of the earliest thymic
precursors (38) and pro-T cells (Fig. 3 A), as observed in
IL-7 /  mice (15). Subcutaneous injection of hGM-CSF
(500 ng   2/day for 8 d) resulted in  10-fold increases in
the number of Gr-1  Mac-1  neutrophils and monocytes as
Figure 1. Cytokine receptor expression in hematopoietic branch points. (A) Lineage relationships of prospectively purified lineage-restricted progeni-
tors in steady-state hematopoiesis. LT-HSC, long-term HSCs (CD34  Lin  Sca-1  c-Kit ); ST-HSC, short-term HSCs (CD34  Lin  Sca-1  c-Kit ).
(B) Results of RT-PCR analyses of cytokine receptors targeted for 250 cells per progenitor species. The symbols under each lane depict relative amounts
of mRNA in each population compared with control cDNA (2   105 cells, bands not shown) by the ratio pixel density units of target cDNA/pixel den-
sity units of control cDNA.  ,  0.1;  , 0.1–0.5;  , 0.5–1.5;   ,  1.5. (C) Expression of transgenic hGM-CSFR  in each purified population.
Shaded and open lines show the staining of target populations by anti–hGM-CSFR  and control IgG antibodies, respectively. A majority of each stem
and progenitor fraction express hGM-CSFR .T
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well as Ter119  erythroid cells in the spleen (not depicted).
However, this treatment did not affect thymocyte numbers
or progenitor frequencies in IL-7 /  hGM-CSF transgenic
mice (Fig. 3 A). The number of CD4  CD8  and CD4 
CD8  mature thymocytes was unchanged. Their mean
numbers were  5   105 and  2   105 cells, respectively,
which were  20-fold less than those in wild-type controls
(not depicted). Thus, ectopic hGM-CSF signals cannot re-
place “trophic” IL-7 signals (20) in T lymphopoiesis.
IL-7 /  mice displayed a differentiation block at the
transition from the pro-B to pre-B stage. The impaired dif-
ferentiation was not restored by the hGM-CSF injection
(Fig. 3 B). Next, we purified IL-7R  /  hGM-CSFR 
and IL-7R  /  hGM-CSFR  B220  CD43  IgM  pro-B
cells, and tested their differentiation on an S17 stromal layer
(Fig. 4). IL-7R  /  hGM-CSFR  pro-B cells differenti-
ated into mature CD19  IgM  B cells in the absence of cy-
tokines. The addition of 20 ng/ml hGM-CSF in the cul-
ture resulted in an unexpected expansion of CD19  B220 
CD3  NK1.1  LGL (Fig. 4 B), which also expressed Mac-
1 at a low level (not depicted). IL-7R  /  hGM-CSFR 
pro-B cells did not mature into B cells in vitro in the pres-
ence of hGM-CSF, indicating that GM-CSF signals cannot
substitute for the nonredundant IL-7 in B lymphopoiesis.
Instead, IL-7R  /  hGM-CSFR  pro-B cells only gave
rise to morphologically mature LGL cells in the presence of
Figure 2. In vitro colony-forming activity of purified stem and pro-
genitors by ectopic hGM-CSF signaling. Clonogenic analysis of stem and
progenitor cells purified from hGM-CSFR transgenic mice. Single cells
were sorted into 96-well plates and cultured in methylcellulose for 8 d in
the presence of cytokine cocktail (Slf, IL-3, IL-11, mGM-CSF, Epo, and
Tpo), hGM-CSF alone, or mGM-CSF alone. 288 single cells were ana-
lyzed in each assay. Note that hGM-CSF alone, like the cytokine cock-
tail, can support formation of all myeloid lineage colonies.
Figure 3. hGM-CSF signals cannot substitute for IL-7 in lymphoid development in vivo. (A) FACS® analysis of thymic progenitor subsets in IL-7–
deficient hGM-CSFR transgenic mice after hGM-CSF injection. In these mice, absolute numbers of thymocytes were  50-fold less than in normal
thymi (not depicted). Note that percentages of the earliest thymic progenitors (TP), pro-T, and pre-T cells did not change by hGM-CSF injection. (B)
FACS® analysis of B cell progenitor subsets in IL-7–deficient hGM-CSFR transgenic mice after hGM-CSF injection. B cell differentiation is blocked at
the pro-B stage, regardless of hGM-CSF injection. Representative data of four mice analyzed in each group.T
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1316 Lymphoid to Myeloid Conversion by Enforced Cytokine Signaling
hGM-CSF. Thus, enforced hGM-CSF signals cannot sub-
stitute for IL-7 signals in T and B cell development but can
stimulate proliferation of an NK-LGL subset. The NK-
LGL population was phenotypically identical to the minor
CD19  B220  CD3-NK1.1  population that is reportedly
included in the B220  CD43  IgM  pro-B fraction (39).
This is consistent with a report by Nishijima et al. (36), in
which in vivo injection of a high dose of hGM-CSF into
hGM-CSFR transgenic mice resulted in an expansion of
Mac-1  NK1.1  NK-LGL cells.
Enforced hGM-CSF Signals Instruct Lineage Conversion into
Myelomonocytic Cells In Vitro. We tested the effect of ec-
topic hGM-CSF signals on myeloid development in lym-
phoid progenitors. hGM-CSFR   CLPs, pro-T, pre-T,
pro-B, and pre-B cells were cultured in liquid media con-
taining only hGM-CSF (Fig. 5). 6 d after the initiation of
culture, CLPs gave rise only to Gr-1  Mac-1  GMs and
Gr-1  Mac-1  Class II (I-Ab)  CD11c  dendritic cells (Fig.
5 A). Because dendritic cells from normal GMPs, but not
from CLPs or pro-T cells, express such high level of Mac-1
(40), the Mac-1  I-Ab  CD11c  cells were categorized into
“myeloid” dendritic cells. Pro-T cells also gave rise to all of
these myeloid cells, whereas pre-T, pro-B, and pre-B cells
did not generate any myeloid cells (not depicted). Clono-
genic, single cell cultures with hGM-CSF alone revealed
that  40% of CLPs and 20% of pro-T cells differentiate
into myeloid cells (Fig. 5, B and C). The frequency of my-
eloid differentiation of hGM-CSFR  CLPs increased up to
55% by the addition of other myeloid cytokines (mGM-
CSF, Slf, IL-11, IL-3, Epo, and Tpo) to hGM-CSF (Fig. 5
B). Thus, a majority of CLPs can readout GM differentia-
tion by ectopic hGM-CSF signals.
We tested whether the myelomonocytic differentiation
potential disappears as CLPs differentiate into the B cell lin-
eage. We cultured hGM-CSFR  CLPs on S17 stromal
cells with IL-7 to promote B cell differentiation, and added
hGM-CSF at different time points. The phenotype of their
progeny was analyzed on day 10 (Fig. 5 D). If we added
hGM-CSF together with IL-7 at the initiation of the cul-
ture, CLPs gave rise to 17% Gr-1  GM cells, 26% Gr-1 
CD19  (Mac-1  CD11c ) dendritic cells, and 57% CD19 
B cells on day 10 under these culture conditions. Percent-
ages of myeloid progeny gradually declined by the delayed
addition of hGM-CSF. When we added hGM-CSF on day
3, CLPs only generated CD19  B cells (Fig. 5 D). These
data indicate that there is a 2-d window after which cul-
tured CLPs cannot convert into the GM lineage. The dis-
appearance of myeloid conversion occurs as cells differenti-
ate into the B cell lineage. This result in turn suggests that
the GM progeny, generated by ectopic hGM-CSF signals,
was not derived from a minority of myeloid contaminants
within the purified CLP fraction.
Myelomonocytic Lineage Conversion Can Occur Even after
Cells Rearranged TCR Genes. To confirm the T lymphoid
origin of GM cells from hGM-CSFR  pro-T cells, we pu-
rified the Gr-1  Mac-1  neutrophil/monocyte progeny of
cultured hGM-CSFR  pro-T cells and tested the rearrange-
ment status of the TCR D 2-J 2. As shown in Fig. 6 A, a
fraction of pro-T–derived Gr-1  Mac-1  cells rearranged
D 2-J 2 genes, indicating that the conversion into the GM
lineage can occur after the D 2-J 2 rearrangement.
Activation of Transcription of Myeloid Genes in Lymphoid
Progenitors During Myelomonocytic Lineage Conversion. The
hGM-CSFR  pro-T cells stimulated by hGM-CSF rapidly
Figure 4. hGM-CSF signals cannot support pro-B cell differentiation but
stimulate large granular lymphocytes with NK phenotype. (A) B220 
CD43  IgM  pro-B cell fraction was cultured on an S17 stromal layer for 14 d,
after which IL-7R /  hGM-CSFR  pro-B cells gave rise to CD19  IgM 
mature B cells in the absence of additional cytokines. IL-7R /  hGM-
CSFR  pro-B fraction gave rise to CD19  B220  NK1.1  CD3  NK cells,
but not mature B cells in the presence of hGM-CSF. (B) Morphology of
CD19  B220  NK1.1  CD3  NK cells. These cells possess coarse cytoplas-
mic granules, which are specific to large granular lymphocytes.T
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Figure 5. hGM-CSF signals can induce lineage switch from the lymphoid to the myeloid
pathways in vitro. (A) FACS® analysis of 200 purified hGM-CSFR  CLPs and pro-T cells cul-
tured in the presence of hGM-CSF alone. Note that both CLPs and pro-T cells give rise to
Gr-1  Mac-1  granulocytes/monocytes (GM) and Mac-1hi CD11c  I-Ab  myeloid dendritic
cells (DC). (B) Clonogenic analysis of myeloid differentiation of CLPs and pro-T cells by ec-
topic hGM-CSF signals. Single cells were cultured in a Terasaki plate in the presence of cyto-
kine cocktail (Slf, IL-3, IL-11, mGM-CSF, Epo, Tpo, and hGM-CSF), hGM-CSF alone, or
mGM-CSF alone. hGM-CSFR  CLPs and pro-T cells exhibit a significant differentiation po-
tential into myeloid lineage cells including granulocytes, monocytes, and dendritic cells at high
frequencies. 240 single cells were analyzed in each assay. (C) Morphology of a single pro-T cell
derived GM colony (top) and a myeloid DC colony (bottom). Giemsa staining:  1,000. (D)
FACS® analysis of progeny of 40 hGM-CSFR  CLPs on an S17 stromal layer in the presence of
10 ng/ml IL-7 for 10 d. 20 ng/ml hGM-CSF was added to the culture at the indicated time
points. Myeloid progeny became undetectable if hGM-CSF was added  2 d after the initiation
of culture.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
1318 Lymphoid to Myeloid Conversion by Enforced Cytokine Signaling
up-regulated GM-affiliated cytokine receptors (mGM-CS-
FR , IL-3R , and G-CSFR), transcription factor (C/
EBP ), and myeloperoxidase (Fig. 6 B), but not MegE-
affiliated EpoR or   globin (unpublished data). In contrast,
hGM-CSFR  pro-B cells did not up-regulate these my-
eloid genes by hGM-CSF stimulation (unpublished data),
indicating that ectopic hGM-CSF signals can reactivate
transcription of GM-affiliated genes only in early T, but
not in B lymphoid progenitors.
Enforced hGM-CSF Signal-induced Myelomonocytic Lineage
Conversion of CLPs Occurs at the Expense of Their Lymphoid
Differentiation In Vivo. We then tested the in vivo effect
of ectopic hGM-CSF signals on differentiation of CLPs.
hGM-CSFR   CLPs were purified from hGM-CSFR
transgenic mice (C57B6-Ly5.2), and transplanted into sub-
lethally irradiated congenic mice (C57B6-Ly5.1) intrave-
nously or intrathymically. Either hGM-CSF (500 ng   2/
day) or control PBS was administered in two groups of
mice for 5 d after the transplantation.
We have previously reported that normal CLPs gener-
ated B and T cells in the spleen peaking at days 14 and 28,
respectively, after intravenous transplantation (23). In con-
trol mice treated with PBS, hGM-CSFR  CLPs gave rise
to B cells on day 14 and, T, B, and NK cells on day 28 in
the spleen, but not to Gr-1  Mac-1  cells (Fig. 7 A, top).
Developing thymocyte progeny was also found in the con-
trol thymi (not depicted). In contrast, in mice treated with
hGM-CSF for the initial 5 d of transplantation, no detect-
able B or T cell progeny was observed on days 14 or 28 in
the spleen (Fig. 7 A) or thymus (not depicted), whereas a
small number of Mac-1  Gr-1  GM progeny was detect-
able on day 28 in the spleen (Fig. 7 A, bottom).
CLPs need to home to the thymic environment for their
T cell readouts (23). To evaluate the effect of ectopic
hGM-CSF signals on thymic T cell development from
CLPs, we injected hGM-CSFR  CLPs directly into the
thymus of congenic mice (Fig. 7 B). In control animals,
progeny of hGM-CSFR  CLPs was undetectable on day 7,
whereas it became detectable on day 14, when hGM-
CSFR  CLPs differentiated into CD4  CD8  double posi-
tive cells as well as CD4  CD8  or CD4  CD8  single pos-
itive cells (Fig. 7 B, top). Gr-1  Mac-1  myelomonocytic
cells were not found in the control thymi throughout the
experiment. In mice treated with hGM-CSF, hGM-
CSFR  CLPs gave rise to Gr-1  Mac-1  GM progeny on
day 7 in the thymus. These myelomonocytic cells disap-
peared on day 14, when only a small number of T cell
progeny was detectable (Fig. 7 B, bottom). Importantly,
the number of day 14 T cell progeny decreased by  40-
fold in hGM-CSF–treated mice (Fig. 7 B). These data indi-
cate that enforced hGM-CSF signals in vivo abrogate lym-
phoid potentials of CLPs, inducing their conversion into
the GM lineage.
Discussion
Lineage potential of hematopoietic progenitors becomes
progressively restricted as cells differentiate into mature
cells. From a mechanistic point of view, it might be rea-
sonable to separate the role of external signals in lineage
commitment into two categories by their functions: (a) lin-
eage permission and (b) lineage instruction. Uncommitted
precursors could be directed to certain lineages, depending
on either or both of these mechanisms. It has been sug-
gested that the maintained accessibility for genes of multi-
ple lineages represent the cells’ immediate lineage potential
(25, 41–43). In our hands, CMPs coexpress myeloery-
throid genes, whereas CLPs coexpress T and B lymphoid
genes at the single cell level (25), and these patterns of
transcription might reflect their chromatin structures al-
ready open for multiple myeloid and lymphoid differentia-
tion programs (3, 43). Thus, one of the simplest models for
lineage commitment is that the permissive signals support
to run differentiation programs that are being transcribed,
whereas the instructive signals turn on silenced differentia-
tion programs that are not transcribed before the stimula-
tion. In this context, the “plasticity” of precursors for lin-
eage commitment could be achieved if instructive signals
Figure 6. hGM-CSFR  pro-T cells pro-
duce GMs with rearranged TCR genes and
up-regulate GM-affiliated genes. (A) TCR
rearrangement analysis of Gr-1   Mac-1 
GMs derived from hGM-CSFR   pro-T
cells. 500 hGM-CSFR  pro-T cells were
cultured in the presence of hGM-CSF for
6 d and FACS®-sorted Gr-1  Mac-1  prog-
eny was used for PCR analysis. (B) RT-PCR
analysis of myeloid genes in hGM-CSFR 
pro-T cells cultured with hGM-CSF. Up-
regulation of myeloid cytokine receptors
and transcription factor is detected, indicat-
ing that hGM-CSF reactivates myeloid dif-
ferentiation programs silenced in normal
pro-T cells.T
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can turn on differentiation programs outside of their phys-
iological lineage potential.
Our data strongly suggest that GM-CSF signals allow the
transcription of both GM and MegE differentiation pro-
grams in stem and myeloerythroid progenitor cells, but do
not activate the GM program in MegE-committed cells.
This is compatible with the previous data that ectopic my-
eloid cytokine signals can support both GM and MegE col-
ony formation (8–11). Because commitment into GM or
MegE lineages appears to occur in a cell-autonomous fash-
ion at least in vitro (44, 45), the down-regulation of GM-
CSFR as a result of commitment into the MegE lineage
should cause MegE cells to become unresponsive to GM-
CSF, thus enabling Epo to critically regulate erythropoiesis.
The “permissive” effect of hGM-CSF signals is myeloid
specific. hGM-CSF signals cannot support lymphoid differ-
entiation through maintaining or up-regulating lymphoid
gene transcription at the CLP or its downstream lymphoid
stages, and cannot replace IL-7 signals that are necessary for
lymphoid development (Figs. 3 and 4; 20). Instead, ectopic
hGM-CSF signals turn on the transcription of myeloid genes
(Fig. 6 B), and induce the GM lineage conversion in a ma-
jority of CLPs and a considerable fraction of pro-T cells (Fig.
5). The GM lineage conversion can occur even in late pro-T
cells with rearranged TCR  genes (Fig. 6 A). Because lym-
phoid progenitors completely shut down myeloid gene tran-
scription (3, 24, 25), this result strongly suggests that hGM-
CSF signals can instruct lymphoid progenitors to become
accessible to myeloid (GM but not MegE) differentiation
programs, presumably through remodeling chromatin structures.
These data indicate that inactivation of genes for unse-
lected lineages and activation of genes for committed lin-
Figure 7. Ectopic hGM-CSF signals inhibit lymphoid differentiation, but promote myelomonocytic lineage conversion of transplanted CLPs in vivo.
(A) 6,000 hGM-CSFR  CLPs (Ly5.2) were intravenously transplanted into congenic mice (Ly5.1). Control mice injected with PBS developed CD19  B
cells on day 14, and CD3  T, CD19  B, and CD3  CD19  (NK1.1 , not shown) NK cells on day 28 in the spleen. Lymphoid differentiation was com-
pletely inhibited in mice that received hGM-CSF, whereas a small number of Gr-1  Mac-1  cells were detectable within the day 28 spleen. (B) 3,000
hGM-CSFR  CLPs (Ly5.2) were directly injected into the thymi of congenic mice (Ly5.1). On day 7, CLP-derived Gr-1  Mac-1  GM cells were found
in the thymus of mice treated with hGM-CSF, whereas no progeny was detectable in control thymi at this time point. On day 14, hGM-CSFR  CLPs
gave rise to CD4  CD8  immature thymocytes and CD4  or CD8  mature thymocytes in control thymi, whereas numbers of CLP-derived thymocytes
were significantly reduced (by  40-fold) in thymi of hGM-CSF–treated mice. In both experiments, two groups of mice (three mice per group) were
subcutaneously injected with either hGM-CSF or control PBS for 5 d after transplantation. Representative data are shown.T
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eages are equally critical in physiological lineage commit-
ment and restriction. GM-CSFR is detectable in short-
term HSCs and CMPs, but not CLPs or their downstream
lymphoid progenitors. GM-CSF signals can induce GM
but not MegE differentiation in CLPs and pro-T cells. Fur-
thermore, in vivo reconstitution experiments showed that
if CLPs receive ectopic GM-CSF signals after transplanta-
tion, they cannot undergo T, B, nor NK lymphoid differ-
entiation, but instead convert into GMPs (Fig. 7). Thus, in
physiological hematopoiesis, CLPs and pro-T cells might
escape from GM commitment signals by losing GM-CSFR
expression. We have recently found that enforced expres-
sion of GATA-1, a major MegE-affiliated transcription fac-
tor, can induce differentiation of CLPs into MegE lineage
cells (46). Accordingly, CLPs possess plasticity for myelo-
erythroid differentiation. They can reactivate GM and
MegE differentiation programs by ectopic signals of cyto-
kines or transcription factors, which are silenced at the CLP
stage in physiological hematopoiesis.
We have reported that ectopic GM-CSF signals sup-
pressed T cell development in fetal thymic organ cultures
especially at the transition from pro-T to pre-T cells (47),
and that hGM-CSF injection induced the significant re-
duction in the number of thymocytes in adult hGM-CSFR
transgenic mice (36). Here we show that the conversion
into the GM lineage by ectopic GM-CSF signals occurs at
the pro-T but not the pre-T stage in vitro, and that ectopic
GM-CSF signals inhibit both T and B cell development
from CLPs inducing their myeloid lineage conversion in
vivo. Thus, our new findings strongly suggest that the inhi-
bition of T lymphopoiesis in the previous report (36, 47)
could result from the GM-CSF–induced myeloid conver-
sion at the CLP and the pro-T stages.
As in the case of ectopic hGM-CSFR, ectopic IL-2R
can mediate signals for GM differentiation in CLPs and
pro-T cells, but not in pro-B cells (27). Interestingly, these
cytokine signals cannot activate GM differentiation in
pro-B cells. In our hands, single cell RT-PCR analysis showed
that all 450 pro-B cells express Pax-5, a critical transcrip-
tion factor for the B cell lineage (25). Pax-5–deficient
pro-B cells are pluripotent (48, 49), and transduction of Pax-5
into myeloid progenitors can suppress proliferation through
blunting responsiveness to myeloid cytokines (50). There-
fore, it is possible that Pax-5 in pro-B cells may suppress
their myeloid differentiation programs through inhibiting
their responsiveness to ectopic myeloid cytokine signals.
The hGM-CSF–induced lymphoid to GM lineage conver-
sion progressively disappears as cells differentiate along the
T cell pathway. hGM-CSF signals cannot reactivate GM
differentiation programs at the further downstream pre-T
stage. King et al. (51) reported that ectopic IL-2R–express-
ing pro-T cells with a TCR D 1-J 1 but not a D 2-J 2
rearrangement can differentiate into GM cells. The exist-
ence of the D 2-J 2 rearrangement in myeloid cells dif-
ferentiated from hGM-CSFR  pro-T cells shown here
suggests that target lymphoid progenitors for lineage con-
version might be slightly different between ectopic IL-2
and hGM-CSF signals.
We and others have reported that CLPs and pro-T cells
but not pre-T or pro-B cells can differentiate into “lym-
phoid” dendritic cells in vitro (40, 52, 53). It is interesting
that the natural loss of dendritic cell generative capacity
and the revealed loss of myeloid conversion from the lym-
phoid pathway occur at similar differentiation stages.
These data raise an interesting possibility that the develop-
ment of “lymphoid” dendritic cells from CLPs and pro-T
cells may represent the residue of their silenced myeloid
potential.
The lineage conversion from the lymphoid to the my-
eloid pathway by ectopic hGM-CSF signals shown here
may be linked to the developmental mechanism of leuke-
mia with “mixed” phenotype (54). In a fraction of acute
myelogenous leukemia, leukemic blasts possess lymphoid
markers including monoclonal rearrangement of TCR
genes (55). Conversely, acute lymphoblastic leukemia or
even myeloma cells occasionally coexpress myeloid fea-
tures (56, 57). Conversion from acute myelogenous leuke-
mia to acute lymphoblastic leukemia or vice versa is also
known to occur (58, 59). These intriguing features of leu-
kemias have been speculated to represent lineage conver-
sions induced by oncogenic events (lineage infidelity; 60,
61). The fact that the lineage conversion could be induced
by ectopic cytokine signals provides a clue to understand-
ing the pathogenesis of mixed lineage leukemia, because a
number of tyrosine kinase fusions share their signaling
pathways with cytokines. For example, BCR-ABL and
TEL fusions directly activate Stat5 (62, 63), which is also a
critical molecule for  c-mediated IL-3/IL-5/GM-CSF
signaling. Thus, our data suggest that the mixed leukemia
phenotype may represent plasticity or “lineage infidelity”
of hematopoietic progenitors.
In summary, hGM-CSF signals alone can maintain the
completion of MegE and GM but not lymphoid differen-
tiation programs. Instead, ectopic hGM-CSF signals reac-
tivate GM differentiation programs in CLPs and pro-T
cells. These results demonstrate significant differences be-
tween cytokine signals required for myeloid and lymphoid
development. Therefore, the organized down-regulation
and up-regulation of cytokine receptors are equally impor-
tant in the maintenance of myeloid and lymphoid hemato-
poiesis. Additional studies on target molecules activated by
lineage-instructive cytokine signals will be crucial in eluci-
dating the mechanism of lineage commitment in normal
and malignant hematopoiesis.
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